DFX Intelligence

Steven Gillis

Managing Directorat Arch Venture Partners· IL

As of 2026-09-23 · this person's identity; each section below carries its own date

Current roles: 2
Investments attributed: 30
Board seats: 14

Ask DFX about this View relationships Find contacts Investments Board seats

As of 2026-09-23 · this person's identity; each section below carries its own date

11 additional roles and seats, 27 additional attributed investments

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

2 deals
12 months
2 investments attributed in the last 12 months; latest SonoThera Form D equity offering ($125M) on 30 Jun 2026.
A partner with a recent deal is actively writing cheques now.
Factfunding announcements and Form D naming the personFor Founders, co-investorsInvestments →
14 boards
seats on record
Sits on 14 boards on record, the latest SonoThera on 30 Jun 2026.
Board seats show where this partner holds governance, not only a cheque.
InferenceForm D directors and board-seat attributionsFor Founders, co-investorsBoard seats →

Relationship network

15 connected entities30 observed investment records8 dated investment records shown here, 2014 to 2026

From the roles sources name this person in, the investments a source attributes to them, and the boards and funds Form D names them on.

Some relationships on this record are counted rather than named here. They open with the full profile.

Click any name or line for the investment records and sources behind it. Line weight is investment records together; dashed lines are inferred.

Reading the network

Organization
Company

Venture relationships are not scored. Each line names its claim: a round led or joined, a board seat or a filing that names the firm, a listing on a portfolio page (dated by when DFX saw it, never by when the investment was made), a disclosed LP commitment, or a co-investor pair counted from observed participations. Observed means a named source says so; Derived means DFX counted it from observed rows; Inferred means a match that may be wrong.

Darker lines were active in the last 24 months or are current; lighter lines are older or undated.

Ask DFX about this network

Which companies and boards is Steven Gillis connected to?

How am I connected?

Name your firm, a company or a person, and DFX finds the published routes to Steven Gillis: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.

See how you connect to Steven Gillis

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Drawing the relationship network…

Roles

1 current, 0 past

Arch Venture Partners Managing Director
Oct 1, 2007 to present · “Schedule A: GILLIS, STEVEN, MANAGING DIRECTOR, since 10/2007, ownership NA, control person N”
Fact Form ADV

Investments attributed to this person

Company	Round	Investor	Attribution	Date	Source
SonoThera, Inc.	Form D equity offering · $125M	Arch Venture Partners	strongly supported · board	Jun 30, 2026	Inference sec.gov
Pheast Therapeutics, Inc.	Form D equity offering · $24.6M	Arch Venture Partners	strongly supported · board	Oct 16, 2025	Inference sec.gov
SonoThera, Inc.	Form D equity offering · $30.4M	Arch Venture Partners	strongly supported · board	Dec 29, 2022	Inference sec.gov

Board seats and vehicles

14 boards, 0 vehicles

SonoThera, Inc. board seat on a deal Jun 30, 2026 Inference
Pheast Therapeutics, Inc. board seat on a deal Oct 16, 2025 Inference
Faraday Pharmaceuticals board seat on a deal Nov 7, 2022 Inference

Timeline

4 dated entries: events, attributed deals, board seats and role changes

Jun 30, 2026
Form D equity offering in SonoThera, Inc. (Arch Venture Partners)
Attributed investment Inference SonoThera, Inc. Form D
Oct 16, 2025
Form D equity offering in Pheast Therapeutics, Inc. (Arch Venture Partners)
Attributed investment Inference Pheast Therapeutics, Inc. Form D
Dec 29, 2022
Form D equity offering in SonoThera, Inc. (Arch Venture Partners)
Attributed investment Inference SonoThera, Inc. Form D
Oct 1, 2007
Joined Arch Venture Partners as Managing Director
Role began Fact Arch Venture Partners Form ADV